EGFR and colorectal carcinoma: We found that 3.0 and 4.0% of the 594 CRC patients (63.6% of COAD, 26.1% of READ and 10.3% of mucinous adenocarcinoma (MUAD)) in the dataset respectively harbored genetically altered EGFR and c-MET (Figure 3A).